Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Short term Debt (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Short term Debt over the past 14 years, most recently at $773000.0 for Q4 2024.

  • For Q4 2024, Short term Debt changed 0.0% year-over-year to $773000.0; the TTM value through Nov 2024 reached $773000.0, changed 0.0%, while the annual FY2024 figure was $773000.0, 33.28% up from the prior year.
  • Short term Debt for Q4 2024 was $773000.0 at Lifecore Biomedical, Inc. \De\, roughly flat from $773000.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $99.0 million in Q4 2022 and troughed at $580000.0 in Q2 2023.
  • A 5-year average of $28.5 million and a median of $11.7 million in 2020 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: skyrocketed 690.52% in 2020 and later plummeted 99.41% in 2023.
  • Year by year, Short term Debt stood at $11.2 million in 2020, then surged by 275.37% to $42.0 million in 2021, then surged by 135.6% to $99.0 million in 2022, then plummeted by 99.22% to $773000.0 in 2023, then changed by 0.0% to $773000.0 in 2024.
  • Business Quant data shows Short term Debt for LFCR at $773000.0 in Q4 2024, $773000.0 in Q3 2024, and $773000.0 in Q2 2024.